ESMO 2017: Adding Everolimus to Letrozole in Metastatic Breast Cancer Therapy
The addition of everolimus to letrozole appears to offer a treatment benefit in patients with estrogen receptor–positive, HER2-negative advanced breast cancer, as shown in BOLERO-4, a phase II, open-label international trial. Thomas Bachelot, MD, of Centre Léon Bérard, Lyon, France, and colleagues found that this combination therapy was effective regardless of patient age, visceral metastases, or bone-only lesions. These results were presented at the 2017 European Society for Medical Oncology (ESMO) Congress (Abstract 244PD).
A total of 202 postmenopausal patients with estrogen receptor–positive, HER2-negative advanced breast cancer were enrolled in the trial. They had no prior therapy for advanced disease.
At data cutoff, median progression-free survival as well as 18- and 24-month Kaplan-Meier–estimated rates of progression-free survival were similar to the full analysis set regardless of patient age, presence/absence of visceral metastases, or presence/absence of bone-only lesions at baseline. The distribution and frequency of all-grade adverse events among the study population were comparable to those of the overall population.